Watchlist

Watchlist
Aradigm Corporation (ARDM)
Aradigm Corporation (ARDM)
Aradigm reports Q1 results
Aradigm (NASDAQ: ARDM ): Q1 EPS of -$0.32 More news on: Aradigm Corp., Earnings news and commentary, Healthcare stocks news, , Read more …
Aradigm Announces First Quarter 2018 Financial Results
Aradigm Corporation (NASDAQ: ARDM) (the Company) today announced financial results for the first quarter and three months ended March 31, 2018. First Quarter 2018 Financial Results The Company recorded $1.5 million in revenue in the first quarter of 2018 compare…
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
A nalysis focus: Conatus Conatus (NASDAQ: CNAT ) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNATs lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor …
EMA accepts Aradigm's marketing application for Linhaliq for certain lung infections; shares ahead 9%
The European Medicines Agency (EMA) has accepted for review Aradigm's ( ARDM +8.6% ) marketing application seeking approval for Linhaliq (ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aerugino…
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung…
Aradigm reports Q4 results
Aradigm (NASDAQ: ARDM ): Q4 EPS of -$0.28 More news on: Aradigm Corp., Earnings news and commentary, Healthcare stocks news, , Read more …
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
Subsequent Highlights Cash and cash equivalents of $7.1 million expected to be sufficient to fund operations for Q1 2018; temporary measures implemented to preserve cash resources Focus on European Approval for Linhaliq Marketing Authorization Application for EU filed …
Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation
Glancy Prongay & Murray LLP (GPM)reminds investors of the March 12, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Aradigm Corporation (Aradigm or the Company) (NASDAQ…
3 Things In Biotech, March 11: Aradigm Retries, Pfizer Glides, VBL Crashes
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec…
Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC
Analysis of top Seeking Alpha coverage: Immuron Today, we will discuss Immuron ( IMRN ) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in …
Aradigm Corporation (ARDM)